Antibiotic Use in Sub-Saharan Africa: Challenges and Strategies

By Crystal Lubbe

October 29, 2024

The article titled “Antibiotic prescription sources and use among under-5 children with fever/cough in sub-Saharan Africa” provides a critical analysis of antibiotic use and prescription sources for children under 5 with fever or cough in sub-Saharan Africa (SSA). In particular, this analysis sheds light on the significant issue of antibiotic misuse, thereby emphasising the necessity for appropriate interventions.

Methodology

The study used data from the Demographic and Health Surveys (DHS) from 2006 to 2021, covering 37 SSA countries and including 18,866 children under 5 with fever or cough.

Main Findings

Overall, the majority of children received antibiotics from unqualified sources, which highlights a significant issue with inappropriate use in the region. Moreover, the study identified that children with formally educated mothers were more likely to receive antibiotics from qualified sources. This finding stressed the vital role of maternal education in improving antibiotic prescription sources.

Implications and Recommendations

Consequently, these findings stress the need to address healthcare disparities, enhance access to qualified providers, and promote maternal education, to ensure proper antibiotic use. Moreover, there is an urgency for targeted interventions and policies to optimise antibiotic prescribing practices and combat AMR in sub-Saharan Africa.

Antimicrobial Resistance

The World Health Organization’s 2022 report highlights AMR as a leading cause of death, attributing 5 million deaths in 2019 to bacterial AMR. The United Nations warns that AMR can lead to 10 million deaths annually by 2050, resulting in severe economic consequences.

Gap in Existing Literature

The study addresses a gap by focusing on children under 5 with fever or cough in SSA. This population has often been overlooked in research, which typically focused on adults or limited simulations in a few countries.

Conclusion

The study offers insights into antibiotic prescription patterns and determinants for children under 5 in sub-Saharan Africa. This stresses the need for effective interventions to ensure proper antibiotic use and reduce antimicrobial resistance risks. Addressing these issues is vital for the health of children in the region.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.